Showing results (1-10 of 21) with videos related to
Sort By:
Pageof 3
Bioorganic & Medicinal Chemistry|August 3, 2010
Design, synthesis, and evaluation of quinazoline T cell proliferation inhibitorsIdit Sagiv-Barfi, Ester Weiss, Alexander LevitzkiSeminars in Radiation Oncology|December 8, 2014
Radiotherapy and toll-like receptor agonistsAurelien Marabelle, Alex Filatenkov, Idit Sagiv-Barfi, et al.Cancer Research|February 9, 2022
Neoadjuvant Intratumoral Immunotherapy with TLR9 Activation and Anti-OX40 Antibody Eradicates Metastatic CancerWan Xing Hong, Idit Sagiv-Barfi, Debra K Czerwinski, et al.Blood|February 10, 2015
Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphomaIdit Sagiv-Barfi, Holbrook E Kohrt, Laura Burckhardt, et al.Science Immunology|May 27, 2022
Intratumoral immunotherapy relies on B and T cell collaborationIdit Sagiv-Barfi, Debra K Czerwinski, Tanaya Shree, et al.The Journal of Infectious Diseases|November 18, 2017
S101, an Inhibitor of Proliferating T Cells, Rescues Mice From Superantigen-Induced ShockAlexei Shir, Shoshana Klein, Idit Sagiv-Barfi, et al.Proceedings of the National Academy of Sciences of the United States of America|March 3, 2015
Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITKIdit Sagiv-Barfi, Holbrook E K Kohrt, Debra K Czerwinski, et al.Science Translational Medicine|February 2, 2018
Eradication of spontaneous malignancy by local immunotherapyIdit Sagiv-Barfi, Debra K Czerwinski, Shoshana Levy, et al.Journal of Immunology (Baltimore, Md. : 1950)|May 31, 2023
Targeted TLR9 Agonist Elicits Effective Antitumor Immunity against Spontaneously Arising Breast TumorsCaitlyn L Miller, Idit Sagiv-Barfi, Patrick Neuhöfer, et al.Cell Chemical Biology|November 14, 2021
Systemic delivery of a targeted synthetic immunostimulant transforms the immune landscape for effective tumor regressionCaitlyn L Miller, Idit Sagiv-Barfi, Patrick Neuhöfer, et al.Pageof 3